Suppr超能文献

微小RNA-17和微小RNA-20b的表达降低通过上调NCOA3促进乳腺癌对紫杉醇治疗的耐药性。

Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3.

作者信息

Ao Xiang, Nie Peipei, Wu Baoyan, Xu Wei, Zhang Tao, Wang Songmao, Chang Haocai, Zou Zhengzhi

机构信息

Breast Oncology Department, Cancer Center of Guangzhou Medical University, Guangzhou, Guangdong, China.

KingMed Diagnostics and KingMed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou, Guangdong, China.

出版信息

Cell Death Dis. 2016 Nov 10;7(11):e2463. doi: 10.1038/cddis.2016.367.

Abstract

Chemoresistance is a major obstacle to effective breast cancer chemotherapy. However, the underlying molecular mechanisms remain unclear. In this study, nuclear receptor coactivator 3 (NCOA3) was found to be significantly increased in taxol-resistant breast cancer tissues and cells. Moreover, overexpression of NCOA3 enhanced breast cancer cell resistance to taxol, whereas depletion of NCOA3 decreased taxol resistance. Subsequently, we investigated whether NCOA3 expression was regulated by miRNAs in breast cancer. By bioinformatics prediction in combination with the data of previous report, miR-17 and miR-20b were selected as the potential miRNAs targeting NCOA3. By real-time PCR analysis, we found that miR-17 and miR-20b were significantly reduced in taxol-resistant breast cancer tissues and cells. In addition, we provided some experimental evidences that miR-17 and miR-20b attenuated breast cancer resistance to taxol in vitro and in vivo models. Furthermore, by luciferase reporter assays, we further validated that both miR-17 and miR-20b directly binded the 3'-untranslated region of NCOA3 mRNA and inhibited its expression in breast cancer cells. Finally, both miR-17 and miR-20b levels were found to be significantly negatively correlated with NCOA3 mRNA levels in breast cancer tissues. Together, our results indicated that loss of miR-17 and miR-20b enhanced breast cancer resistance to taxol by upregulating NCOA3 levels. Our study suggested miR-17, miR-20b and NCOA3 may serve as some predictive biomarkers and potential therapeutic targets in taxol-resistant breast cancer treatment.

摘要

化疗耐药是乳腺癌有效化疗的主要障碍。然而,其潜在的分子机制仍不清楚。在本研究中,发现核受体辅激活因子3(NCOA3)在耐紫杉醇乳腺癌组织和细胞中显著增加。此外,NCOA3的过表达增强了乳腺癌细胞对紫杉醇的耐药性,而NCOA3的缺失则降低了紫杉醇耐药性。随后,我们研究了在乳腺癌中NCOA3的表达是否受miRNA调控。通过生物信息学预测并结合先前报道的数据,选择miR-17和miR-20b作为靶向NCOA3的潜在miRNA。通过实时PCR分析,我们发现miR-17和miR-20b在耐紫杉醇乳腺癌组织和细胞中显著降低。此外,我们提供了一些实验证据,表明miR-17和miR-20b在体外和体内模型中均可减弱乳腺癌对紫杉醇的耐药性。此外,通过荧光素酶报告基因测定,我们进一步验证了miR-17和miR-20b均直接结合NCOA3 mRNA的3'-非翻译区并抑制其在乳腺癌细胞中的表达。最后,发现miR-17和miR-20b水平在乳腺癌组织中均与NCOA3 mRNA水平显著负相关。总之,我们的结果表明,miR-17和miR-20b的缺失通过上调NCOA3水平增强了乳腺癌对紫杉醇的耐药性。我们的研究表明,miR-17、miR-20b和NCOA3可能作为耐紫杉醇乳腺癌治疗中的一些预测生物标志物和潜在治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ff3/5260895/17393cababe8/cddis2016367f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验